Elicio Therapeutics (ELTX) Amortization of Deferred Charges (2020 - 2021)
Elicio Therapeutics posted quarterly Amortization of Deferred Charges of $1.9 million for Q1 2021, up 1100.0% year-on-year from $157000.0 in Q1 2020, and down 61.72% on a QoQ basis from $4.9 million in Q4 2020.
Elicio Therapeutics (ELTX) has 2 years of Amortization of Deferred Charges data on file, last reported at $1.9 million in Q1 2021.
- For the quarter ending Q1 2021, Amortization of Deferred Charges rose 1100.0% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2021 stood at $1.9 million (down 75.41% YoY), and the FY2021 full-year result was $1.9 million, down 75.41% from the prior year.
- Amortization of Deferred Charges for Q1 2021 stood at $1.9 million, down from $4.9 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $4.9 million in Q4 2020 and bottomed at $157000.0 in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1.88 Mn |
| Mar 31, 2021 | 1.88 Mn |
| Dec 31, 2020 | 4.92 Mn |
| Dec 31, 2020 | 4.92 Mn |
| Sep 30, 2020 | 2.19 Mn |
| Sep 30, 2020 | 2.19 Mn |
| Jun 30, 2020 | 396,000.00 |
| Jun 30, 2020 | 396,000.00 |
| Mar 31, 2020 | 157,000.00 |
| Mar 31, 2020 | 157,000.00 |